You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Correlating TCR diversity to immune reconstitution after cord blood transplant

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NHLBI

    DESCRIPTION provided by applicant Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA matched sibling or unrelated donor Transplants using stem cells from umbilical cord blood provide an alternative for these patients allowing transplantation to proceed with less stringent HLA matching requirements Unfortunately in addition to t ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Long non coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases

    SBC: IQuity Labs, Inc.            Topic: NIAID

    No other group of diseases encompasses a greater pathophysiology than do the rheumatic diseases Spanning multiple organ systems clinical decisions often rely on coordinated efforts from primary care providers and rheumatologists to rule in or rule out differential diagnoses when treating inflammatory conditions such as rheumatoid arthritis RA and systemic lupus erythematosus SLE RA is a sym ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Innovative Effective RNA based Vaccine for Chikungunya Virus

    SBC: PAI LIFE SCIENCES INC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Chikungunya virus CHIKV is an emerging disease of global public health importance Originally identified in sporadic CHIKV outbreaks occurred in Africa and Asia for several decades Beginning with an outbreak on the island of La Reunion in the virus has continued to spread to new regions around the globe CHIKV is now endemic in the Caribbean is present in t ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Aerosol Sampling and Microfluidic Analysis of Reactive Oxygen Species

    SBC: ILLIONIX, LLC            Topic: 113

    DESCRIPTIONprovided by applicantCardiovascular diseases and Asthma affects betweenandmillion people in the United States includingmillion childrenduring the pastyearsits incidence worldwide has doubledAsthma is responsible formillion person days of restricted activity anddeaths per yearamounting to $billion in direct heath related coststhere is uncertainty about the specific factors that are contr ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Fixed site and wearable monitors for assessment of personal exposure to airborne chemicals

    SBC: XPLOSAFE LLC            Topic: 113

    Project Summary Abstract People in all facets of life are exposed to volatile toxins that may cause them to unexplainably sicken The NIEHS Exposure Biology and Exposome Program has the ambitious and worthy goal to track a person s exposures from conception to death and correlate these with biological responses and health outcomes Achieving this goal will require numerous inexpensive sensors that ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical Evaluation of Ancestral Coagulation Factor VIII

    SBC: EXPRESSION THERAPEUTICS, LLC            Topic: NHLBI

    ABSTRACT The development of transformative therapeutics including the possibility of a cure though gene therapy is the sole mission of Expression Therapeutics and continues to be a major research and development activity in the overall $ B USD hemophilia market space However progress in the field has been limited by significant hurdles including the size complexity instability immunogenic ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Media based youth e cig prevention toolkit for community based organizations

    SBC: KDH Research & Communication, Inc.            Topic: NIDA

    KDH Research andamp Communication KDHRC submits this Fast Track SBIR proposal to develop and evaluate AVOID Anti Vaping Online Information Dissemination a media based online toolkit to support community based organizations CBO prevention programming against youth e cigarette e cig use Youth e cig use also known as vaping is a rapidly growing public health threat with use among hi ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Novel sanitizer against viral infections with long lasting effect

    SBC: CAMELLIX, LLC            Topic: NIAID

    Project Summary Abstract Despite mandatory use of hand sanitizer on cruise ships there are reported cruise ship onboard norovirus outbreaks in exceeded the number of norovirus outbreaks outbreaks onboard cruise ships in One of the problems of currently available alcohol based hand sanitizer is that alcohol evaporates in less than seconds after each application to a surface ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease

    SBC: LEFLORE TECHNOLOGIES LLC            Topic: 400

    Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Anti CCL mAb to treat castration resistant prostate cancer

    SBC: JYANT Technologies, Inc.            Topic: 102

    Metastatic castration resistant prostate cancer CRPC PCa accounts for of PCa deaths and is associated with skeletal metastases CRPC affects patients differently making this disease difficult for physicians to provide standardized treatments with similar outcomes Docetaxel can prolong the overall survival in patients with metastatic CRPC but current therapies do not provide a cure Doce ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government